Attention Deficit Hyperactivity Disorder (ADHD) Stimulant Medications for Employer Plans
Customize your policy alerts
Sign up for Cigna Policy IP0477 alerts
Get alerted when Policy IP0477 changes without checking for updates manually.
Monitor payer policy activity
Criteria for medical necessity and prior authorization of stimulant medications for Attention Deficit Hyperactivity Disorder (ADHD) for Cigna employer plans, including brand and generic interchangeability, step therapy, and special formulation considerations.
Updated preferred product requirements for multiple stimulant products (e.g., Adderall, Adderall XR, Adzenys XR-ODT, Concerta, Mydayis, Xelstrym, and many others).
Added amphetamine extended-release orally disintegrating tablets (generic for Adzenys XR-ODT) to the policy.
Arynta (lisdexamfetamine dimesylate oral solution) was added to the policy with preferred product requirements.
Removed Adhansia XR from the policy.
Added a policy statement and removed the documentation statement and documentation requirements.
Coverage Criteria for Stimulant Medications
Adzenys XR-ODT / amphetamine ER ODT (and generic equivalents)
Covered when criteria below are met
Previous history of use of a dexmethylphenidate or methylphenidate product may count toward trials where noted.
Arynta / lisdexamfetamine oral solution and related agents
Covered when one of the following is met
Concerta, Jornay PM, and methylphenidate ER brands
Covered when criteria are met depending on age and prior trials
Previous history of use of an amphetamine product would count towards trials where noted.
Previous history of use of an amphetamine product would count towards trials.
Dexedrine and dextroamphetamine products
Covered when meeting age-based and trial requirements
Previous history of dexmethylphenidate or methylphenidate use counts toward trial.
Dyanavel XR, Evekeo ODT, Focalin, and other immediate/extended-release agents
Coverage contingent on multiple prior trials or age-based exceptions
Previous history of use counts toward trials where noted.
Initial and continuation therapy general criteria
Coverage allowed when required prior trials or exceptions are met (examples below capture the document's AND/OR logic snippets present in these chunks).
See product-specific nodes for exact required trials.
This can satisfy an initial trial requirement for both <18 and ≥18 pathways.
Examples include trials of amphetamine mixed ER/IR, lisdexamfetamine, dexmethylphenidate ER, methylphenidate ER/IR, dextroamphetamine, methamphetamine depending on formulation requested.
Methylphenidate ER product criteria
Product-level criteria examples as present in text:
Applies prior to coverage of specified product formulations.
Mydayis (mixed salts) criteria
Previous history of use of dexmethylphenidate or methylphenidate counts toward trial.
Methylphenidate IR product criteria
Previous amphetamine use counts toward trial.
Lisdexamfetamine product criteria
Previous history of use of an amphetamine product counts toward trial.
Transdermal system criteria
Captures alternative pathway for transdermal when swallowing issues exist.
No additional blanket exclusions are listed beyond the standard medical necessity requirements. Coverage is denied when the criteria — including required step-therapy trials, prior failures or significant intolerance of specified alternative agents, or the formulation-difference exception documentation — are not met. Requests may be denied if required prior therapies or required documentation are missing.
Stimulant medications indicated for ADHD are not medically necessary when prescribed for indications outside ADHD. The policy explicitly states that ADHD stimulants for any other use will be denied (examples include fatigue associated with multiple sclerosis, neuroenhancement, and weight loss except limited short-term approved indications).
The Conditions Not Covered section was clarified by removing the prior phrase referencing CNS stimulants in long-term combination therapy with atomoxetine; this operational change refines the policy language and may affect prior denial rationale related to combination therapy.
Coverage of branded stimulant products generally requires documented failure or significant intolerance to required generic or alternative stimulant agents, or documentation that the patient cannot use the bioequivalent generic because of a formulation-difference causing a significant allergy or serious adverse reaction. Use of a branded product without such documented trials or an approved formulation-difference exception does not meet medical necessity.
Specific uses are listed as not medically necessary, including: 1) fatigue associated with multiple sclerosis; and 2) long-term (>2 months) combination therapy with atomoxetine (language clarified in recent revisions). In addition, requests for branded products without required prior trials or without documentation of inability to use the bioequivalent generic will not meet medical necessity.
Initial Therapy Requirements
Initial therapy with formulation-difference exception
Initial therapy (patient new to ADHD stimulant therapy)
This allows brand coverage for initial therapy when generic intolerance/allergy to inactive ingredients is documented.
Initial therapy
Initial therapy (patient new to ADHD stimulant therapy) criteria examples as presented:
Document inability to take generic due to inactive ingredient differences when applicable.
Continuation Therapy Requirements
Continuation therapy requirements
Continuation therapy for patients currently receiving ADHD stimulant therapy
Continuation therapy
Continuation therapy requires prior trials or documented intolerance/failure of specified agents or documentation of formulation-difference allergy exception.
Examples vary by product; previous history of use counts toward trials.
Step Therapy Trials and Tables
| Step requirement | Details |
|---|---|
| Trial(s) of specified stimulant alternatives | |
| Patient must have tried and, per the prescriber, experienced inadequate efficacy OR significant intolerance with specified alternatives such as amphetamine mixed extended‑release (ER) capsules (generic for Adderall XR), lisdexamfetamine capsules or chewable tablets (generic for Vyvanse), and where noted dexmethylphenidate or methylphenidate products may count toward required trials; inability to swallow solids or inability to ingest prescribed dosage with sprinkle‑capable products provides an alternate pathway. |
| Agents to try and fail | Example requirement |
|---|---|
| Amphetamine products (mixed ER, ER ODT, IR) | |
| Examples include amphetamine mixed ER capsules (generic for Adderall XR), amphetamine ER ODT tablets (generic for Adzenys XR‑ODT), and amphetamine IR formulations; patient must have documented inadequate efficacy OR significant intolerance to the listed amphetamine agents per product‑specific criteria. | |
| Lisdexamfetamine (Vyvanse) | |
| Lisdexamfetamine capsules or chewable tablets (generic for Vyvanse) — required as part of combination trials for some products (e.g., Adzenys XR‑ODT, Dyanavel XR) or as an alternative that must be tried and failed depending on the product and age branch. | |
| Dexmethylphenidate (Focalin) — ER or IR | |
| Dexmethylphenidate ER or IR (generic for Focalin/Focalin XR) may be required to be tried and failed in combination with methylphenidate ER products prior to coverage of some branded products (eg, methylphenidate ER 45/63/72 mg, Mydayis pathways). | |
| Methylphenidate ER/IR (Ritalin, Aptensio, Concerta) | |
| Methylphenidate ER capsules (generic for Aptensio XR) or IR formulations (Ritalin/generic) are listed as required trials or may count toward required trials; some product criteria require failure of BOTH dexmethylphenidate ER and methylphenidate ER prior to coverage. |
| Preferred product / multi-source brand update | Impact on step therapy |
|---|---|
| Preferred product requirements updated and extended | |
| Preferred product requirements were updated to multi‑source brand criteria and extended to Standard, Performance and Legacy formularies for multiple stimulant products (examples include Vyvanse capsules and chewables, Adderall formulations, Adzenys XR‑ODT, Concerta, Mydayis, Xelstrym, and others). | |
| Operational additions/removals | |
| Policy additions include amphetamine ER ODT tablets (generic for Adzenys XR‑ODT) and Arynta (lisdexamfetamine oral solution) with preferred product requirements; Adhansia XR was removed. These changes may alter or imply step edits tied to preferred product criteria across formularies. |
Provider Actions, Prior Authorization, and Documentation
Prior authorization required; document prior trials or formulation-difference exception
Prior authorization is required for specific branded stimulant products. The request must document prior trials of the alternative specified stimulant products or provide documentation that the patient cannot use the bioequivalent generic due to an inactive-ingredient formulation difference (e.g., dyes, fillers, preservatives) that, per the prescriber, would cause a significant allergy or serious adverse reaction.
- Examples: Adzenys XR-ODT requests require trials of amphetamine mixed ER capsules and lisdexamfetamine or a swallowing/formulation exception (see product criteria).
- Arynta requests require trials of two listed alternatives or documented inability to use sprinkle/open products per criteria.
PA requires documented prior trials or documented inability to use bioequivalent generic
Prior authorization determinations require documentation that the patient tried and had inadequate efficacy or significant intolerance with the specified bioequivalent generic products or listed alternative agents, or a prescriber-justified exception when the patient cannot take the generic because of inactive-ingredient differences.
- Formulation-difference exception examples reference dyes, fillers, preservatives as reasons the prescriber may permit brand coverage.
- Exceptions also include inability to swallow solid oral dosage forms when sprinkle-capable alternatives are insufficient.
PA influenced by updated preferred product criteria and formulary changes
Updates to preferred product requirements and additions/removals of specific stimulant products may affect prior authorization outcomes; providers should verify formulary-preferred status at the time of request.
- Revision notes list multiple updated preferred product requirements (e.g., Vyvanse, Adderall, Adzenys XR-ODT, Mydayis) and extension to Standard/Performance/Legacy formularies.
- Products have been added (e.g., Arynta) and removed (Adhansia XR) which can change PA expectations.
Step therapy required: fail specified generics/alternatives first
Step therapy applies for many branded stimulant agents — coverage is contingent on documented failure (inadequate efficacy) or significant intolerance to one or more specified generics or other stimulant brands prior to approval.
- Value/Advantage/Total Savings plans commonly require trials of multiple alternatives (e.g., amphetamine mixed ER, amphetamine ER ODT, lisdexamfetamine).
- Standard/Performance plans may treat some brands as non-preferred with step edits noted.
Document specific step therapy trials and failures
When step therapy is required, providers must document trials and failures (inadequate efficacy) or significant intolerance to the specific agents listed for the requested product before coverage will be approved.
- Examples: methylphenidate ER products require failure of dexmethylphenidate ER and methylphenidate ER generics.
- Mydayis and transdermal systems require trials of listed mixed-salts ER generics or amphetamine/lisdexamfetamine alternatives per age-based branches.
Required step trials: try and fail listed agents (examples provided)
Step therapy trials must show inadequate efficacy or significant intolerance to the listed agents; previous history of use of certain amphetamine/methylphenidate products may count toward required trials where noted.
- Examples include trials of dexmethylphenidate ER (Focalin XR generic), methylphenidate ER (Aptensio XR generic), amphetamine mixed ER (Adderall XR generic), or lisdexamfetamine (Vyvanse generic).
- Prescribers should indicate which prior products were tried and the clinical outcome (inefficacy or intolerance).
Required clinical documentation: prescriber attestation of trials and formulation-difference reason
Prescriber attestation is required to support prior trials and to document that the bioequivalent generic cannot be used due to a formulation-difference allergy or serious adverse reaction.
- Attestation must identify which product(s) were tried and state whether the patient had inadequate efficacy or significant intolerance.
- If claiming a formulation-difference exception, document the specific inactive ingredient concern (e.g., dye, filler, preservative) and the adverse reaction risk per the prescriber.
Document prior trials and any inactive-ingredient allergies/intolerances
Prescribers must document prior trials, inadequate efficacy or significant intolerance, or allergy to inactive ingredients to support step therapy exemptions or formulation-difference exceptions.
- Documentation should include which generic/bioequivalent products were tried and the clinical reason they were inadequate or intolerable.
- Allergy or serious adverse reaction to inactive ingredients must be described to justify brand coverage.
Documentation statement removed — continue to provide required trial/allergy details
A documentation statement and certain documentation requirements were removed in recent revisions; however, clinical documentation of prior trials and formulation-difference exceptions remains part of the criteria for many products.
- Revision notes state: 'Added a policy statement. Removed the documentation statement and documentation requirements.'
- Providers should follow current PA submission guidance and include necessary trial/allergy details despite the removed generic documentation statement.
Denial risk if prior therapy requirements not met or documented
Requests lacking documentation that required prior therapies were tried (or documented failures/intolerances) may be denied.
- Example: Adzenys XR-ODT requests may be denied if the patient has not trialed amphetamine mixed ER and lisdexamfetamine as required in the criteria.
- Denials may occur when step therapy or age-based required trials are not met or documented.
Denial risk when formulation-difference exception is not documented
If a prescriber claims a formulation-difference exception but does not document the patient’s inability to use the bioequivalent generic because of an inactive-ingredient allergy or serious adverse reaction, the request may be denied.
- Formulation-difference examples cite dyes, fillers, preservatives as inert ingredients that could cause a significant allergy per the prescriber.
- Providers must state why the generic cannot be used and the specific adverse reaction risk.
Denial risk: indications listed as not medically necessary
Use of ADHD stimulant medications for indications listed as not medically necessary (for example, fatigue associated with multiple sclerosis, long-term combination therapy with atomoxetine >2 months, neuroenhancement, weight loss) will be denied.
- The policy lists fatigue associated with MS and long-term (>2 months) combination therapy with atomoxetine among not medically necessary uses.
- Other not covered uses include neuroenhancement and weight loss except limited FDA-indicated short-term use for specific agents.
Conditions Not Covered language clarified — may affect prior denial rationale
Conditions Not Covered language was clarified in revisions (phrase related to long-term combination therapy with atomoxetine removed); this change may alter prior denial rationale for combination therapy in some cases.
- Revision notes state the phrase referencing CNS stimulants in long-term combination therapy with atomoxetine was removed for clarity.
- Providers should note the updated Conditions Not Covered wording when appealing or documenting combination-therapy cases.
Definitions and References
Background and Scope
This policy sets coverage conditions for stimulant medications used to treat Attention Deficit Hyperactivity Disorder (ADHD). It distinguishes initial therapy (including allowance for a formulation-difference exception when a patient cannot tolerate a bioequivalent generic due to inactive-ingredient allergy) from continuation therapy (which requires prior trials and evidence of inadequate efficacy or significant intolerance to specified alternatives). Age-based differences apply across product-specific criteria.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.